Trade
Cannabis: cannabinoids
Starting January 1, 2028, CBN isolate joins CBD isolate outside California’s definition of cannabis concentrate.
The law aligns cannabinoid rules with California’s industrial-hemp framework while clarifying cannabis-market tracking and enforcement powers.
What the law does
- Excludes CBD and CBN isolates from the controlled-substances definition of cannabis concentrate beginning January 1, 2028.
- Clarifies that cannabis track-and-trace records cover cultivation, harvest, processing, manufacturing, distribution, inventory, sale, and delivery.
- Allows seizure of cannabis or cannabis products possessed, stored, offered for sale, or sold at an unlicensed premises.
- Bars cigarette and tobacco sellers from making any sale of cannabis, cannabis products, or products presumed to be cannabis, and authorizes related seizures.
- Clarifies that products containing or claiming to contain cannabinoids are presumed cannabis products unless shown to comply with industrial-hemp rules or to qualify as industrial hemp.
- Permits compliance-fund money to be used to seize and destroy any product seized under cigarette and tobacco licensing law.
Who it affects
- Producers and sellers of CBD and CBN isolates.
- Licensed cannabis businesses and their track-and-trace software providers.
- Unlicensed cannabis sellers and premises.
- Cigarette and tobacco retailers.
Context
The law takes effect alongside broader industrial-hemp and cannabinoid changes enacted in AB 8.